In response to Buckeye’s question

...what would the potential market be like for those specific indications? »

The IDF website gives data on the numbers of diabetics worldwide. It’s more than 400 million, and expected to be more than 600 million in 20 years’ time. If 10% have eGFR<60, that’s 40-60 million people who might take a daily dose of apabetalone for their lifetimes if the FDA approves.

Then there’s the possibility that the China DA might regard P=0.06 good enough, and that ALL Chinese diabetics should take apabetalone to prevent CVD. There are about 115 million diabetics in China, and rising every year.

https://www.idf.org/our-network/regions-members/western-pacific/members/101-china.html